Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer,
negatively expresses estrogen receptor, progesterone receptor, and the human epidermal …

Triple negative breast cancer (TNBC) is a subtype of breast cancer, with estrogen receptor,
human epidermal growth factor receptor 2 and progesterone receptor negative. TNBC is …

Purpose of review Triple negative breast cancer (TNBC) accounts for approximately 10–
15% of all breast cancers and it is associated with a poor prognosis. However, recent new …

Triple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype
among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes …

Simple Summary Triple negative breast cancer (TNBC) represents 15 to 20% of all breast
cancers in the United States. The main treatment option remains chemotherapy, despite …

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer,
which is characterized by the absence of estrogen receptor (ER) and progesterone receptor …

Triple-negative breast cancer (TNBC) is characterized by a lack of expression of estrogen
receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 …

Triple‑negative breast cancer (TNBC) accounts for 10‑15% of all breast cancer cases.
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …

Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers and is
associated with poor long-term outcomes compared with other breast cancer subtypes …

Triple-negative breast cancer (TNBC) is known to have a poor prognosis and limited
treatment options, namely chemotherapy. Different molecular studies have recently …